Anavex Life Sciences Corp (AVXL)

[McMagyar]

And if they present or when they present 24 weeks data from OLE..
They have access always to this data..
They are basically practicing precision medicine right now on 480 patients in OLE!

The super responders high dosage will Maintain Higher Scores( little improvement but little decline )
The low dosage will become Super Reaponders.. over 50% will have better scores at end than at start
The placebo group.. now that they get medicine at night.. more will be titrated to higher dose successfully.. let’s say we have 150.. it is early ad.. so even with 48 week delay.. most will have enough S1r signature to be properly affected..I think
we will have over 50% respond from this group with high S1r expression..
I will say we still get 100!

The OLE data is going to be as impressive as the Phase 2b/3!

And we have PDD Ole data as well..

Anavex has ALL THIs DATA!
When they say it works..


THEY KNOW IT WORKS!